David Moller

David is a physician-scientist with more than two decades of experience leading drug discovery and development across a broad range of therapeutic areas. Before joining Third Rock, he held senior R&D leadership roles at Merck and Eli Lilly, where he led programs in cardiometabolic, renal, and musculoskeletal diseases—efforts that contributed to the development and approval of multiple breakthrough therapies, including Januvia, Trulicity, and Mounjaro.

Most recently, David served as chief scientific officer in several biotech companies, focusing on rare, metabolic, pulmonary, and inflammatory diseases. His deep cross-TA expertise, strong scientific instincts, and expansive network across academia and industry make him a valuable contributor to Third Rock’s discovery engine.

David began his career as a faculty member at Harvard Medical School. He earned his M.D. from University of Cincinnati and holds an undergraduate degree from Brown University. He continues to bring a clinical lens to complex drug discovery efforts, driving toward maximal therapeutic impact. 

When he’s not engaged in trailblazing science, David can be found boating, skiing, fishing—and mastering the art of seafood paella(!).